|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Ciba-Geigy
gptkb:Searle_Pharmaceuticals
|
|
gptkbp:activities
|
dopamine receptor antagonist
serotonin receptor antagonist
|
|
gptkbp:appointed_by
|
intramuscular injection
oral capsule
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Geodon
|
|
gptkbp:class
|
atypical antipsychotic
|
|
gptkbp:clinical_trial
|
60%
Phase III
|
|
gptkbp:contraindication
|
concurrent use of certain medications
hypersensitivity to ziprasidone
|
|
gptkbp:dosage_form
|
40 mg to 160 mg daily
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
suspension
oral tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ziprasidone
|
|
gptkbp:indication
|
acute mania
mixed episodes
|
|
gptkbp:ingredients
|
C21 H24 N4 OS
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:is_atype_of
|
N05 A E01
|
|
gptkbp:is_available_on
|
generic medication
|
|
gptkbp:is_monitored_by
|
gptkb:weight
blood glucose
lipid levels
|
|
gptkbp:is_used_for
|
schizophrenia
bipolar disorder
|
|
gptkbp:lifespan
|
7 hours
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:marketed_as
|
gptkb:Geodon
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:release_region
|
gptkb:government_agency
gptkb:Australia
gptkb:India
gptkb:Japan
gptkb:Monarch
gptkb:United_Kingdom
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:side_effect
|
nausea
restlessness
drowsiness
cardiovascular events
dry mouth
weight gain
hyperglycemia
extrapyramidal symptoms
QT prolongation
neuroleptic malignant syndrome
|
|
gptkbp:type_of
|
138105-41-3
|